The article outlines treatments for different types of heart failure: HFrEF, HFmrEF, and HFpEF. Medications like ACE inhibitors, MRAs, beta-blockers, and ARNI are recommended for HFrEF, while HFmrEF patients may benefit from treatments used for HFrEF. However, effective medications for HFpEF are lacking. New drugs such as SGLT2 inhibitors, omecamtiv mecarbil, and vericiguat show promise for HFrEF. ARNI, notably effective in reducing exacerbations and mortality, is expected to become a cornerstone treatment. Additionally, drugs like ivabradine and SGLT2 inhibitors offer added benefits, contributing to the evolving landscape of heart failure management. There needs further research and trials to further increase survival rate of heart failure patients.